International audienceDespite important human and financial resources and considerable accumulation of scientific publications, patents, and clinical trials, cancer research has been slow in achieving a therapeutic revolution similar to the one that occurred in the last century for infectious diseases. It has been proposed that science proceeds not only by accumulating data but also through paradigm shifts. Here, we propose to use the concept of 'paradigm shift' as a method of investigation when dominant paradigms fail to achieve their promises. The first step in using the 'paradigm shift' method in cancer research requires identifying its founding paradigms. In this review, two of these founding paradigms will be discussed: (i) the reifica...
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and in...
We discuss philosophical, methodological, and biomedical grounds for the traditional paradigm of can...
Cancer research is drawing on the human genome project to develop new molecular-targeted treatments....
International audienceDespite important human and financial resources and considerable accumulation ...
Cancer is widely considered an abnormality that emerges from within the body and which must be destr...
This article argues that the excessive focus on cancer as an insidious living defect that needs to b...
Advances in our understanding of cancer biology and discoveries emerging from cancer genomics are be...
This review paper is intended to bring together common features of two important new approaches to c...
During the past decade, cancer drug development has shifted from a focus on cytotoxic chemotherapies...
Over just the past few years, cancer immunotherapy has transformed how we think about cancer care an...
Theoretical and empirical work over the past several decades suggests that oncogenesis and disease p...
The paradigm of the Somatic Mutation Theory (SMT) is failing, and a new paradigm is underway but not...
Despite the productivity of basic cancer research, cancer continues to be a health burden to society...
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution-NonC...
Despite the productivity of basic cancer research, cancer continues to be a health burden to society...
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and in...
We discuss philosophical, methodological, and biomedical grounds for the traditional paradigm of can...
Cancer research is drawing on the human genome project to develop new molecular-targeted treatments....
International audienceDespite important human and financial resources and considerable accumulation ...
Cancer is widely considered an abnormality that emerges from within the body and which must be destr...
This article argues that the excessive focus on cancer as an insidious living defect that needs to b...
Advances in our understanding of cancer biology and discoveries emerging from cancer genomics are be...
This review paper is intended to bring together common features of two important new approaches to c...
During the past decade, cancer drug development has shifted from a focus on cytotoxic chemotherapies...
Over just the past few years, cancer immunotherapy has transformed how we think about cancer care an...
Theoretical and empirical work over the past several decades suggests that oncogenesis and disease p...
The paradigm of the Somatic Mutation Theory (SMT) is failing, and a new paradigm is underway but not...
Despite the productivity of basic cancer research, cancer continues to be a health burden to society...
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution-NonC...
Despite the productivity of basic cancer research, cancer continues to be a health burden to society...
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and in...
We discuss philosophical, methodological, and biomedical grounds for the traditional paradigm of can...
Cancer research is drawing on the human genome project to develop new molecular-targeted treatments....